NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.

Nyxoah SA (NASDAQ:NYXH) is set to release its Q2 2025 earnings on Aug 18, 2025. The consensus estimate for Q2 2025 revenue is ...

Analysts estimate that Nyxoah will report an earnings per share (EPS) of $-0.63. Nyxoah bulls will hope to hear the company ...

The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Nyxoah SA may now help make dreams come true here in the U.S. with its FDA approval for the Genio system for the treatment of ...

Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

Investing.com -- Nyxoah SA (BR:NYXH) (NASDAQ: NYXH) stock jumped 9.4% following FDA approval of its Genio system for treating moderate to severe obstructive sleep apnea (OSA).

The US FDA has granted approval to Nyxoah’s Genio system for treating individuals with moderate to severe obstructive sleep ...